RecruitingNCT06527157
Investigations of Reproductive Cancers in Women
PROspective ACcrual To Investigate reprOductive Cancers in womeN
Sponsor
PinkDx, Inc.
Enrollment
4,500 participants
Start Date
Jul 30, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this study is to create a non-invasive diagnostic test to rule out gynecological cancer in females aged 45 and older with abnormal uterine or postmenopausal bleeding.
Eligibility
Sex: FEMALEMin Age: 45 YearsMax Age: 100 Years
Inclusion Criteria6
- Evidence of a personally signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the study.
- Willing and able to comply with scheduled visits, study plan, and other procedures.
- Expected to be available for the duration of the study and can be contacted by telephone during study participation.
- Females aged 45 and older (with roughly 80% of enrolled subjects over the age of 50).
- Presence of uterus.
- AUB or PMB being worked up to diagnose the cause of the bleeding
Exclusion Criteria8
- Investigator site staff members directly involved in the conduct of the study and their family members or subjects who are PinkDx, Inc. employees or their family members.
- Other medical or psychiatric conditions that would increase the risk of study participation in the judgement of the Investigator.
- Women who have had a hysterectomy.
- Women with a known history of endometrial cancer or uterine sarcoma.
- Women who have received prior treatment for endometrial cancer.
- Inability or unwillingness to sign informed consent.
- Clinical suspicion of pregnancy.
- Women who have used a tampon within 7 days of sample collection.
Locations(16)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06527157
Related Trials
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
NCT057586883 locations
Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking
NCT059776211 location
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT0557936667 locations
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
NCT063691552 locations
Cancer Loyalty Card Study 2 (CLOCS-2)
NCT064470641 location